Gene expression signature with independent prognostic significance in epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 22, Issue 23, 2004, Pages 4648-4658

  Spentzos, Dimitrios ^a   Levine, Douglas A ^a   Ramoni, Marco F ^a   Joseph, Marie ^a   Gu, Xuesong ^a   Boyd, Jeff ^a   Libermann, Towia A ^a   Cannistra, Stephen A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SURVIVAL; DNA FINGERPRINTING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; ADJUVANT CHEMOTHERAPY; ADULT; AGED; CANCER STAGING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; NEOPLASM; OVARIECTOMY; OVARY TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT OUTCOME;

COMPLEMENTARY DNA; RNA; TUMOR MARKER;

ADULT; AGED; BIOPSY, NEEDLE; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARIECTOMY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 12344267687     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.04.070     Document Type: Article

References (48)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 329:1550-1559, 1993
2. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
3. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al: Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20:463-466, 2002
4. Boyd J, Sonoda Y, Federici MG, et al: Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260-2265, 2000
5. Cass I, Baldwin RL, Varkey T, et al: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187-2195, 2003
6. Rubin SC: BRCA-related ovarian carcinoma. Cancer 97:2127-2129, 2003
7. Tai YT, Lee S, Niloff E, et al: BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 16:2583-2590, 1998
8. Golub TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286:531-537, 1999
9. Armstrong SA, Staunton JE, Silverman LB, et al: MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30:41-47, 2002
10. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
11. Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68-74, 2002
12. Ruel M, Bianchi C, Khan TA, et al: Gene expression profile after cardiopulmonary bypass and cardioplegic arrest. J Thorac Cardiovasc Surg 126:1521-1530, 2003
13. Mitsiades N, Mitsiades CS, Richardson PG, et al: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 101:2377-2380, 2003
14. Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci U S A 101:540-545, 2004
15. Mitsiades N, Mitsiades CS, Poulaki V, et al: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 99:14374-14379, 2002
16. Califano A, Stolovitzky G, Tu Y: Analysis of gene expression microarrays for phenotype classification. Proc Int Conf Intell Syst Mol Biol 8:75-85, 2000
17. Califano A: SPLASH: Structural pattern localization analysis by sequential histograms. Bioinformatics 16:341-357, 2000
18. Klein U, Tu Y, Stolovitzky GA, et al: Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194:1625-1638, 2001
19. Klein U, Tu Y, Stolovitzky GA, et al: Gene expression dynamics during germinal center transit in B cells. Ann N Y Acad Sci 987:166-172, 2003
20. Klein U, Tu Y, Stolovitzky GA, et al: Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci U S A 100:2639-2644, 2003
21. Kuppers R, Klein U, Schwering I, et al: Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest 111:529-537, 2003
22. Lepre J, Rice JJ, Tu Y, et al: Genes@Work: An efficient algorithm for pattern discovery and multivariate feature selection in gene expression data. Bioinformatics, 2004
23. Pomeroy SL, Tamayo P, Gaasenbeek M, et al: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415:436-142, 2002
24. Ramaswamy S, Ross KN. Lander ES, et al: A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54, 2003
25. Ramaswamy S, Tamayo P, Rifkin R, et al: Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 98:15149-15154, 2001
26. Wu B, Abbott T, Fishman D, et al: Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data. Bioinformatics 19:1636-1643, 2003
27. Kim S: Protein beta-turn prediction using nearest-neighbor method. Bioinformatics 20:40-44, 2004
28. Beer DG, Kardia SL, Huang CC, et al: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816-824, 2002
29. Ntzani EE, Ioannidis JP: Predictive ability of DNA microarrays for cancer outcomes and correlates: An empirical assessment. Lancet 362:1439-1444, 2003
30. Henriksen R, Funa K, Wilander E, et al: Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53: 4550-4554, 1993
31. Shawver LK, Schwartz DP, Mann E, et al: Ihibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res 3:1167-1177, 1997
32. Thant AA, Nawa A, Kikkawa F, et al: Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin Exp Metastasis 18:423-428, 2000
33. Sakamoto M, Kondo A, Kawasaki K, et al: Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 14:305-315, 2001
34. Auersperg N, Pan J, Grove BD, et al: E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci U S A 96:6249-6254, 1999
35. Jechlinger M, Grunert S, Tamir IH, et al: Expression profiling of epithelial plasticity in tumor progression. Oncogene 22:7155-7169, 2003
36. Thiery JP, Chopin D: Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev 18:31-42, 1999
37. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454, 2002
38. Tran NL, Nagle RB, Cress AE, et al: N-Cadherin expression in human prostate carcinoma cell lines: An epithelial-mesenchymal transformation mediating adhesion with Stromal cells. Am J Pathol 155:787-798, 1999
39. Vincent-Salomon A, Thiery JP: Host microenvironment in breast cancer development: Epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 5:101-106, 2003
40. Kuhn W, Schmalfeldt B, Reuning U, et al: Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 79:1746-1751, 1999
41. Harbeck N, Kruger A, Sinz S, et al: Clinical relevance of the plasminogen activator inhibitor type 1-a multifaceted proteolytic factor. Onkologie 24:238-244, 2001
42. Konecny G, Untch M, Pihan A, et al: Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 7:1743-1749, 2001
43. Chambers SK, Ivins CM, Carcangiu ML: PIasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 79:449-454, 1998
44. Seki N, Kodama J, Hashimoto I, et al: Thrombospondin-1 and -2 messenger RNA expression in normal and neoplastic endometrial tissues: Correlation with angiogenesis and prognosis. Int J Oncol 19:305-310, 2001
45. Kodama J, Hashimoto I, Seki N, et al: Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor. Anticancer Res 21:2983-2987, 2001
46. Hsieh CY, Chen CA, Chou CH, et al: Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: Implications for malignant ascites formation and tumor lymphangiogenesis. J Biomed Sci 11:249-259, 2004
47. Ueda M, Terai Y, Kumagai K, et al: Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells. Gynecol Oncol 82:162-166, 2001
48. Yokoyama Y, Charnock-Jones DS, Licence D, et al: Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 88: 237-244, 2003